Artal Group’s Accelerate Diagnostics AXDX Stock Holding History

Artal Group’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-50,000	Closed	-$11.5M	–	106
2018 Q3	$11.5M	Hold	50,000	–	–	0.3%	47
2018 Q2	$11.2M	Buy	+50,000	New	+$11.2M	0.24%	42

Other funds holding AXDX

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

GAM

Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Artal Group's AXDX Position: Q4 2020 in Review

Artal Group sold out of Accelerate Diagnostics (AXDX) in Q4 2020, closing a stake of 42,750 shares — an estimated $4.56M sold.

Artal Group first reported a position in AXDX in Q2 2017 and held it in 14 quarters. The position peaked at $13.1M in Q4 2017. 115 funds tracked by Wall St. Rank hold AXDX as of Q4 2020.

Artal Group reported no remaining Accelerate Diagnostics position as of Q4 2020 after selling out during the quarter.
Artal Group sold 42,750 Accelerate Diagnostics shares in Q4 2020, an estimated $4.56M.
Artal Group first reported a position in Accelerate Diagnostics in Q2 2017 and held it in 14 quarters.
Artal Group's Accelerate Diagnostics position peaked at $13.1M in Q4 2017.
115 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2020.

Based on Artal Group's 13F filing for Q4 2020, filed 11 Feb 2021.